Translating Microbiome Futures

A Global Translational Roadmap

Nature Biotechnology and Global Engage convened a panel of leaders in the microbiome field including CEOs and CSOs of several microbiome companies, representatives from big pharmas working in the space, and top academics to discuss the current state of the art in human microbiome research and its translation into therapies.

Covering a range of key issues that included the regulatory landscape, the spectrum of modalities, the variety of potential therapeutic and preventative applications, and pre-clinical, clinical and manufacturing challenges, the main outcomes of the discussion have now been summarized and published in Nature Biotechnology.

We invite you to read this insightful piece by filling in the form opposite. 

The Microbiome Futures project was produced with support from the following sponsors: Takeda PharmaceuticalQuay PharmaceuticalsDiversigenQiagen and Taconic Biosciences.

Featuring:

  • Bernat Olle, CEO, Vedanta Biosciences
  • Arpita Maiti, Senior Director, External Science & Innovation, Pfizer 
  • Denise Kelly, Venture Partner and Investment Advisor, Seventure
  • Elodie Ghedin, Director, NYU Center for Genomics and Systems Biology
  • Richard Bonneau, Director, NYY Center for Data Science
  • Dan Littman, Helen L. and Martin S. Kimmel Professor of Molecular Immunology, Department of Pathology Professor, NYU

Read the report